Insider · CIK 0001830755
James C Hamilton
Files at ARWR (ARROWHEAD PHARMACEUTICALS, INC.). First filing Jan 7, 2025, latest Mar 9, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ARWR: ARROWHEAD PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | ARROWHEAD PHARMACEUTICALS, INC. | $642k 10,000 shares | -4% | +537% from low-13% from high | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | $2.5M 40,164 shares | -19% | +539% from low-10% from high | |
| 16Weak | ARROWHEAD PHARMACEUTICALS, INC. | $700k 20,000 shares | -9% | +250% from low0% from high | |
| 12Weak | ARROWHEAD PHARMACEUTICALS, INC. | $450k 15,000 shares | -6% | +198% from low0% from high | |
| 11Weak | ARROWHEAD PHARMACEUTICALS, INC. | $375k 15,000 shares | -6% | +157% from low-3% from high | |
| 7Weak | ARROWHEAD PHARMACEUTICALS, INC. | $200k 10,000 shares | -4% | +100% from low-24% from high | |
| 35Weak | ARROWHEAD PHARMACEUTICALS, INC. | $649k 32,729 shares | -11% | +10% from low-26% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -10,000 | $64.19 | $642k | 236,958 | Mar 9, 2026 |
| Jan 6, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 246,958 | Jan 8, 2026 |
| Jan 5, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -4,625 | $61.24 | $283k | 207,497 | Jan 5, 2026 |
| Jan 5, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -6,090 | $62.28 | $379k | 201,407 | Jan 5, 2026 |
| Jan 5, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -14,792 | $63.01 | $932k | 186,615 | Jan 5, 2026 |
| Jan 5, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -12,711 | $63.95 | $813k | 173,904 | Jan 5, 2026 |
| Jan 5, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,200 | $64.49 | $77k | 172,704 | Jan 5, 2026 |
| Jan 5, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -437 | $65.97 | $29k | 172,267 | Jan 5, 2026 |
| Jan 5, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -309 | $68.00 | $21k | 171,958 | Jan 5, 2026 |
| Oct 1, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -20,000 | $35.00 | $700k | 212,122 | Oct 3, 2025 |
| Sep 12, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -15,000 | $30.00 | $450k | 232,122 | Sep 16, 2025 |
| Sep 2, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -15,000 | $25.00 | $375k | 247,122 | Sep 4, 2025 |
| Aug 13, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -611 | $20.00 | $12k | 271,511 | Aug 15, 2025 |
| Aug 15, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -9,389 | $20.00 | $188k | 262,122 | Aug 15, 2025 |
| Jan 4, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | AGrant or award Common Stock10b5-1 | +100,000 | $0.00 | $0 | 304,851 | Jan 7, 2025 |
| Jan 6, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -21,758 | $19.68 | $428k | 283,093 | Jan 7, 2025 |
| Jan 6, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -10,971 | $20.11 | $221k | 272,122 | Jan 7, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.